NCT Number: NCT05283330
Phase: Phase 1
Trial Summary: A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of 212Pb-DOTAM-GRPR1 in subjects with various GRPR-exp – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Orano Med LLC
Acronym:
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives